1. Home
  2. CERT vs CTMX Comparison

CERT vs CTMX Comparison

Compare CERT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CERT

Certara Inc.

HOLD

Current Price

$6.33

Market Cap

860.9M

Sector

Technology

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.90

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
CTMX
Founded
2008
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
860.9M
977.1M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
CERT
CTMX
Price
$6.33
$3.90
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$11.67
$12.10
AVG Volume (30 Days)
2.5M
3.4M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$418,838,000.00
$76,201,000.00
Revenue This Year
$4.18
N/A
Revenue Next Year
$5.39
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
8.75
N/A
52 Week Low
$5.19
$1.72
52 Week High
$13.88
$8.21

Technical Indicators

Market Signals
Indicator
CERT
CTMX
Relative Strength Index (RSI) 55.41 36.51
Support Level $5.93 $3.83
Resistance Level $6.48 $3.91
Average True Range (ATR) 0.28 0.25
MACD 0.04 -0.03
Stochastic Oscillator 76.87 3.96

Price Performance

Historical Comparison
CERT
CTMX

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: